A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

NCT04419623 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
Sars-CoV2
Cancer
Solid Tumor
Carcinoma
Blood Cancer

Interventions

DRUG: TL-895

Sponsor

Telios Pharma, Inc.